FORMULATION, DEVELOPMENT AND EVALUATION OF METOCLOPRAMIDE FAST DISSOLVING TABLETS
Shivam Upadhyay, Reena Shende, Teena parmar & Chandani Gupta, Dr. Satkar Prasad
ABSTRACT
Metoclopramide is a widely used antiemetic and gastroprokinetic drug, known for its efficacy in treating nausea, vomiting, and gastrointestinal disorders. The conventional tablet dosage form of Metoclopramide has limitations in terms of its slow dissolution and subsequent delayed onset of action. To address these limitations and improve patient compliance, the present study focuses on the formulation, development, and evaluation of Metoclopramide fastdissolving tablets (FDTs). The formulation of Metoclopramide FDTs was optimized using superdisintegrants, such as croscarmellose sodium, crospovidone, and sodium starch glycolate, to promote rapid tablet disintegration and dissolution. Various excipients were evaluated to achieve the desired mouthfeel, taste-masking, and stability of the tablets. The optimized formulation was prepared by direct compression technique, and the tablets were characterized for their physical appearance, weight variation, hardness, friability, disintegration time, and drug content. In vitro dissolution studies demonstrated that the Metoclopramide FDTs had significantly enhanced drug release compared to conventional tablets. The FDTs achieved a higher percentage of drug release within a short span, leading to faster drug absorption and onset of action. The optimized formulation of Metoclopramide FDTs demonstrated excellent performance in terms of physical characteristics, disintegration time, drug content, and dissolution rate. These results suggest that the formulated FDTs hold promise as a patient-friendly dosage form with improved therapeutic efficacy and faster relief from symptoms.The development of Metoclopramide FDTs offers a valuable alternative to conventional tablets, particularly for patients who have difficulty swallowing or require rapid relief from symptoms. Further studies, including stability testing and in vivo evaluations, will be essential to confirm the long-term stability, bioavailability, and therapeutic effectiveness of the developed Metoclopramide fast-dissolving tablets.
[Full Text Article]